Real-world Efficacy and Safety of Stapokibart in Children and Adolescents with Moderate-to-severe Atopic Dermatitis: A Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0258Keywords:
atopic dermatitis, children, adolescent, treatment outcome, safety, stapokibartAbstract
Paediatric real-world evidence for stapokibart in moderate-to-severe atopic dermatitis (AD) is scarce. We retrospectively analysed 55 patients aged 6–17 years treated at a single centre for 16 weeks using weight-tiered dosing (<30 kg: 600 mg loading, then 300 mg every 4 weeks; ≥30 kg: 600 mg loading, then 300 mg every 2 weeks). Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), body surface area (BSA), Investigator’s Global Assessment (IGA), Children’s Dermatology Life Quality Index (CDLQI) and Pruritus Numerical Rating Scale (P-NRS) were assessed at baseline and weeks 4, 8, 12 and 16. At week 16, median EASI fell from 10.0 to 1.95 and SCORAD from 46.2 to 13.3; P-NRS from 8.0 to 1.0 and CDLQI from 14.0 to 4.0. Week 16 response rates were 92.7% (EASI-50), 70.9% (EASI-75), 38.2% (EASI-90), 52.7% (IGA 0/1) and 67.3% (P-NRS≤2). Mild adverse events occurred in 9.1%. Stapokibart was associated with rapid improvements in disease severity, itch and quality of life and was well tolerated in routine paediatric care.
Downloads
References
Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 2007; 215: 123– 129. DOI: https://doi.org/10.1159/000104263
Kong TS, Han TY, Lee JH, Son SJ. Correlation between severity of atopic dermatitis and sleep quality in children and adults. Ann Dermatol 2016; 28: 321–326. DOI: https://doi.org/10.5021/ad.2016.28.3.321
Kim JH, Samra MS. Moderate to severe atopic dermatitis in children: focus on systemic Th2 cytokine receptor antagonists and Janus kinase inhibitors. Clin Exp Pediatr 2024; 67: 64–79. DOI: https://doi.org/10.3345/cep.2022.00346
Mahmoud O, Yosipovitch G, Attia E. Burden of disease and unmet needs in the diagnosis and management of atopic dermatitis in the Arabic population of the Middle East. J Clin Med 2023; 12: 4675. DOI: https://doi.org/10.3390/jcm12144675
Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, et al. Patient-reported outcomes in adults with moderate-tosevere atopic dermatitis treated with stapokibart over 52 weeks: a post hoc analysis of a phase 3 trial. Adv Ther 2025; 42: 4527–4539. DOI: https://doi.org/10.1007/s12325-025-03284-7
Zhao Y, Zhou C, Man X, Liu B, Geng S, Liang Y, et al. Efficacy and safety of extending dosing interval of stapokibart in patients with atopic dermatitis. Dermatitis 2025: 17103568251361896. DOI: https://doi.org/10.1177/17103568251361896
Zhao M, Xu Z, Wu L, Wei Z, Yang B, Lin Z, et al. Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label singlearm phase Ib/IIa trial. Br J Dermatol 2026; 194: 621–628. DOI: https://doi.org/10.1093/bjd/ljaf455
Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis. Acad Dermatol Venereol 2023; 37: 1046–1055. DOI: https://doi.org/10.1111/jdv.18849
Chiricozzi A, Gori N, Di Nardo L, Antonelli F, Caruso C, Caldarola G, et al. Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumabtreated patients. Dermatology 2022; 238: 717–724. DOI: https://doi.org/10.1159/000519361
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44–56. DOI: https://doi.org/10.1001/jamadermatol.2019.3336
Kovalenko P, Kamal MA, Davis JD, Huniti N, Xu C, Bansal A, et al. Base and covariate population pharmacokinetic analyses of dupilumab in adolescents and children ≥6 to <12 years of age using phase 3 data. Clin Pharmacol Drug Dev 2021; 10: 1345–1357. DOI: https://doi.org/10.1002/cpdd.986
Kamal MA, Kovalenko P, Kosloski MP, Srinivasan K, Zhang Y, Rajadhyaksha M, et al. The posology of dupilumab in pediatric patients with atopic dermatitis. Clin Pharmacol Ther 2021; 110: 1318–1328. DOI: https://doi.org/10.1002/cpt.2366
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
